A Phase 4 interventional study of Dulaglutide and Placebo in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 25 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-09-24.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 27th largest by enrollment, is one of 3 that started in 2016, is one of 9 in phase 4, and was the 31st registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 159 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 121st largest by enrollment of the 232 interventional ones that give a count, is one of 7 that started in 2016, is one of 33 in phase 4, and was the 118th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy and safety of combination therapy with dulaglutide and insulin in Japanese participants with type 2 diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dulaglutide 0.75 milligram (mg) administered once weekly for 16 weeks. After 16-weeks, dulaglutide administered once weekly for 36 weeks.
Drug: Dulaglutide
Placebo administered once weekly for 16 weeks. After 16-weeks, dulaglutide 0.75 mg administered once weekly for 36 weeks.
Drug: Dulaglutide · Drug: Placebo
Administered subcutaneously (SC)
Also known as: LY2189265
Administered SC
Change From Baseline in Hemoglobin A1c (HbA1c)
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) mean in HbA1c was calculated using a restricted maximum likelihood (REML) based mixed-effects model for repeated measures (MMRM) and adjusted by, baseline HbA1c, treatment, visit, and treatment-by-visit insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin), where participant treated as a random effect.
Time frame: Baseline, Week 16
Percentage of Participants With HbA1c <7.0% or ≤6.5%
Percentage of participants whose HbA1c was \<7.0% or ≤6.5%. HbA1c \<7.0% is presented.
Time frame: Week 16
Change From Baseline in Fasting Serum Glucose (FSG)
The LS mean change from baseline in FSG was calculated using a REML based MMRM and adjusted by, baseline value, treatment, visit, treatment-by-visit, baseline HbA1c Group (\<8.5%, \>=8.5%) + insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin), where participant treated as a random effect.
Time frame: Baseline, Week 16
Change From Baseline in Plasma Glucose From 7-Point Self-Monitored Blood Glucose Profiles (SMBG)
The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: prebreakfast blood glucose (BG), breakfast 2-hour postprandial blood glucose (PPBG), prelunch BG, lunch 2-hour PPBG, predinner BG, dinner 2-hour PPBG, and bedtime BG. LS mean was calculated with fixed effect test of analysis of covariance (ANCOVA) model and adjusted by, baseline value, treatment, baseline HbA1c Group (\<8.5%, ≥8.5%), insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin).
Time frame: Baseline, Week 16
Change From Baseline in Body Weight
LS mean change from baseline in body weight was calculated using a REML based MMRM and was adjusted by, baseline value, treatment, visit, treatment-by-visit, baseline HbA1c group (\<8.5%, \>=8.5%), insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin), where participant treated as a random effect.
Time frame: Baseline, Week 16
Change From Baseline in Daily Total Insulin Dose
Mean change from baseline in total insulin dose was measured in each treatment groups.
Time frame: Baseline, Week 16
| Milestone | Placebo | Dulaglutide |
|---|---|---|
| Started | 39 | 120 |
| Received at least one dose of study drug | 39 | 120 |
| Completed | 37 | 117 |
| Not completed | 2 | 3 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Placebo | Dulaglutide |
|---|---|---|
| Started | 37 | 117 |
| Completed | 31 | 111 |
| Not completed | 6 | 6 |
| Withdrew: Adverse event | 5 | 3 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 |
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) mean in HbA1c was calculated using a restricted maximum likelihood (REML) based mixed-effects model for repeated measures (MMRM) and adjusted by, baseline HbA1c, treatment, visit, and treatment-by-visit insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin), where participant treated as a random effect.
| percentage of HbA1c | Placebo | Dulaglutide |
|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) | 0.06 ± 0.099 | -1.45 ± 0.057 |
Percentage of participants whose HbA1c was \<7.0% or ≤6.5%. HbA1c \<7.0% is presented.
| percentage of participants | Placebo | Dulaglutide |
|---|---|---|
| Percentage of Participants With HbA1c <7.0% or ≤6.5% | 47.4 | 0 |
The LS mean change from baseline in FSG was calculated using a REML based MMRM and adjusted by, baseline value, treatment, visit, treatment-by-visit, baseline HbA1c Group (\<8.5%, \>=8.5%) + insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin), where participant treated as a random effect.
| milligram/deciliter (mg/dL) | Placebo | Dulaglutide |
|---|---|---|
| Change From Baseline in Fasting Serum Glucose (FSG) | -4.1 ± 4.94 | -34.2 ± 2.78 |
The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: prebreakfast blood glucose (BG), breakfast 2-hour postprandial blood glucose (PPBG), prelunch BG, lunch 2-hour PPBG, predinner BG, dinner 2-hour PPBG, and bedtime BG. LS mean was calculated with fixed effect test of analysis of covariance (ANCOVA) model and adjusted by, baseline value, treatment, baseline HbA1c Group (\<8.5%, ≥8.5%), insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin).
| mg/dL | Placebo | Dulaglutide |
|---|---|---|
| Prebreakfast BG | 12.30 ± 4.37 | -14.28 ± 2.52 |
| Breakfast 2-hour PPBG | 13.15 ± 7.35 | -32.24 ± 4.19 |
| Prelunch BG | 8.08 ± 5.56 | -28.74 ± 3.18 |
| Lunch 2-hour PPBG | 10.74 ± 7.39 | -39.42 ± 4.54 |
| Predinner BG | 5.66 ± 5.74 | -25.61 ± 3.28 |
| Dinner 2-hour PPBG | 3.97 ± 7.91 | -30.99 ± 4.48 |
| Bedtime BG | 13.21 ± 7.78 | -28.24 ± 4.45 |
LS mean change from baseline in body weight was calculated using a REML based MMRM and was adjusted by, baseline value, treatment, visit, treatment-by-visit, baseline HbA1c group (\<8.5%, \>=8.5%), insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin), where participant treated as a random effect.
| kilogram (kg) | Placebo | Dulaglutide |
|---|---|---|
| Change From Baseline in Body Weight | -0.30 ± 0.302 | -0.20 ± 0.171 |
Mean change from baseline in total insulin dose was measured in each treatment groups.
| International Units (IU)/Day | Placebo | Dulaglutide |
|---|---|---|
| Change From Baseline in Daily Total Insulin Dose | -0.3 ± 1.2 | -1.1 ± 3.1 |
Collected over Up to 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Double-Blind (DB) Treatment Period | 0/39 (0%) | 0/39 (0%) | 18/39 (46.2%) |
| Dulaglutide 0.75 mg DB Treatment Period | 0/120 (0%) | 3/120 (2.5%) | 47/120 (39.2%) |
| Placebo DB Treatment, Dulaglutide 0.75 mg Extension Period | 0/39 (0%) | 1/39 (2.6%) | 28/39 (71.8%) |
| Dulaglutide 0.75 mg DB Treatment/Extension Period | 0/120 (0%) | 6/120 (5%) | 59/120 (49.2%) |
| Event | Placebo Double-Blind (DB) Treatment Period | Dulaglutide 0.75 mg DB Treatment Period | Placebo DB Treatment, Dulaglutide 0.75 mg Extension Period | Dulaglutide 0.75 mg DB Treatment/Extension Period |
|---|---|---|---|---|
| DepressionPsychiatric disorders | 0/39 | 0/120 | 1/39 | 0/120 |
| Suicide attemptPsychiatric disorders | 0/39 | 0/120 | 1/39 | 0/120 |
| CataractEye disorders | 0/39 | 0/120 | 0/39 | 1/120 |
| Large intestine polypGastrointestinal disorders | 0/39 | 0/120 | 0/39 | 1/120 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/39 | 1/120 | 0/39 | 1/120 |
| MyositisMusculoskeletal and connective tissue disorders | 0/39 | 1/120 | 0/39 | 1/120 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/39 | 1/120 | 0/39 | 1/120 |
| Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/39 | 0/120 | 0/39 | 1/120 |
| Event | Placebo Double-Blind (DB) Treatment Period | Dulaglutide 0.75 mg DB Treatment Period | Placebo DB Treatment, Dulaglutide 0.75 mg Extension Period | Dulaglutide 0.75 mg DB Treatment/Extension Period |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 7/39 | 19/120 | 12/39 | 34/120 |
| Abdominal discomfortGastrointestinal disorders | 1/39 | 10/120 | 5/39 | 11/120 |
| ConstipationGastrointestinal disorders | 4/39 | 8/120 | 5/39 | 13/120 |
| DiarrhoeaGastrointestinal disorders | 0/39 | 5/120 | 3/39 | 10/120 |
| DyspepsiaGastrointestinal disorders | 1/39 | 2/120 | 3/39 | 2/120 |
| VomitingGastrointestinal disorders | 2/39 | 3/120 | 3/39 | 6/120 |
| InfluenzaInfections and infestations | 0/39 | 2/120 | 3/39 | 5/120 |
| Decreased appetiteMetabolism and nutrition disorders | 0/39 | 8/120 | 2/39 | 9/120 |
| NauseaGastrointestinal disorders | 2/39 | 7/120 | 2/39 | 7/120 |
| PalpitationsCardiac disorders | 1/39 | 1/120 | 2/39 | 2/120 |
All randomized participants who received at least one dose of study drug.
| Age, Continuous(years) | Placebo | Dulaglutide | Total |
|---|---|---|---|
| Mean | 59.1 ± 10.68 | 59.3 ± 10.23 | 59.3 ± 10.31 |
| Sex: Female, Male(Participants) | Placebo | Dulaglutide | Total |
|---|---|---|---|
| Female | 19 | 42 | 61 |
| Male | 20 | 78 | 98 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Dulaglutide | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 39 | 120 | 159 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Dulaglutide | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 39 | 120 | 159 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | Dulaglutide | Total |
|---|---|---|---|
| Japan | 39 | 120 | 159 |
| Percentage of Hemoglobin A1c (HbA1c) at Baseline(Percentage of HbA1c) | Placebo | Dulaglutide | Total |
|---|---|---|---|
| Mean | 8.64 ± 0.72 | 8.50 ± 0.69 | 8.53 ± 0.70 |
| Percentage of Participants with Insulin regimen(percentage of insulin regimen) | Placebo | Dulaglutide | Total |
|---|---|---|---|
| Basal | 43.6 | 43.3 | 43.4 |
| Premixed | 23.1 | 21.7 | 22.0 |
| Basal/meal time | 33.3 | 35.0 | 34.6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Aug 2016, a primary completion of Jun 2018 and a completion of Jun 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2019, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide